Ascendis Pharma A (ASND) Non-cash Items (2015 - 2026)
Ascendis Pharma A (ASND) posted Non-cash Items of -$9.5 million for Q1 2026, up 92.75% sequentially from -$130.4 million in Q4 2025, and up 48.69% YoY from -$6.4 million in Q1 2025.
Ascendis Pharma A (ASND) Non-cash Items (2015 - 2026) Analysis & Trends
Ascendis Pharma A has reported Non-cash Items for 12 years, with the latest figure at -$9.5 million in Q1 2026.
- Quarterly Non-cash Items rose 48.69% year-over-year to -$9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132.9 million (up 42.16% YoY) and the FY2025 annual result came in at -$143.8 million, up 55.12% from the prior year.
- Non-cash Items improved to -$9.5 million in Q1 2026 per ASND's latest filing, from -$130.4 million in the prior quarter.
- Over five years, Non-cash Items peaked at $4.6 million in Q3 2025 and troughed at -$163.1 million in Q2 2023.
- A 5-year average of -$88.2 million and a median of -$101.6 million in 2022 frame the typical range for Non-cash Items.
- The sharpest annual moves came in 2022 and 2025: Non-cash Items plunged 49.32% in 2022, then soared 107.31% in 2025.
- Over 5 years, Non-cash Items stood at -$101.6 million in 2022, then slumped by 36.76% to -$138.9 million in 2023, then jumped by 35.51% to -$89.6 million in 2024, then sank by 45.59% to -$130.4 million in 2025, then surged by 92.75% to -$9.5 million in 2026.
- According to Business Quant data, Non-cash Items over the past three periods registered -$9.5 million, -$130.4 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.45 Mn |
| Mar 31, 2026 | -9.45 Mn |
| Dec 31, 2025 | -130.45 Mn |
| Dec 31, 2025 | -130.45 Mn |
| Sep 30, 2025 | 4.64 Mn |
| Sep 30, 2025 | 4.64 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | -18.42 Mn |
| Mar 31, 2025 | -18.42 Mn |
| Dec 31, 2024 | -89.60 Mn |
| Dec 31, 2024 | -89.60 Mn |
| Sep 30, 2024 | -63.46 Mn |
| Sep 30, 2024 | -63.46 Mn |
| Jun 30, 2024 | -58.30 Mn |
| Jun 30, 2024 | -58.30 Mn |
| Mar 31, 2024 | -113.08 Mn |
| Mar 31, 2024 | -113.08 Mn |
| Sep 30, 2023 | -138.94 Mn |
| Sep 30, 2023 | -138.94 Mn |